Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2022 16:04 ET | Source: Athira Pharma, Inc.

Athira Files Definitive Proxy Statement and Mails Letter to Shareholders

Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card Highlights successful...
April 04, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

BOTHELL, Wash., April 04, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 30, 2022 12:12 ET | Source: Athira Pharma, Inc.

Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future

BOTHELL, Wash., March 30, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 24, 2022 16:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

On track to report topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer’s disease study in 3Q22 Conference call today at 4:30...
March 21, 2022 07:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 21, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Participate in Two Upcoming Investor Conferences

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 20, 2022 04:50 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 17, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 14, 2022 07:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress

BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
March 02, 2022 14:15 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Active metabolite of fosgonimeton (ATH-1017) enhances the HGF/MET system, resulting in neurotrophic and procognitive effects In two unique disease models, ATH-1020 reduces depression-like...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right